DLEU7-AS1: A Potential Drug Target and Biomarker (G100874074)

Target Name: DLEU7-AS1

NCBI ID: G100874074

DLEU7-AS1

Other Name(s): DLEU7 antisense RNA 1

DLEU7-AS1: A Potential Drug Target and Biomarker

DLEU7-AS1, a gene encoding a protein involved in the development and progression of cancer, has emerged as a promising drug target and biomarker for cancer treatment. The protein is expressed in various tissues and has been associated with cancer-related processes, including tumor growth, angiogenesis, and metastasis.

Recent studies have identified DLEU7-AS1 as a potential drug target by its expression in various cancer types, including breast, ovarian, and colorectal cancer. Additionally, the protein has been shown to play a role in the development of cancer-associated fibrosis, a condition characterized by the excessive production of extracellular matrix proteins.

DLEU7-AS1 has also been identified as a potential biomarker for cancer diagnosis and treatment. The protein has been shown to be expressed in various cancer types, including breast, ovarian, and colorectal cancer, and has been used as a marker for cancer diagnosis and monitoring.

Targeting DLEU7-AS1

DLEU7-AS1 is a protein that can be targeted by small molecules, including anti-cancer drugs. One approach to targeting DLEU7-AS1 is to use inhibitors that can reduce the levels of the protein in cancer cells.

Anti-cancer drugs that have been shown to target DLEU7-AS1 include inhibitors of the PI3K/Akt signaling pathway, which is a pathway involved in cancer cell growth and survival. This pathway is thought to be involved in the regulation of DLEU7-AS1 expression, and inhibitors of this pathway have been shown to reduce the levels of DLEU7-AS1 in cancer cells.

Another approach to targeting DLEU7-AS1 is to use antibodies that recognize the protein and can bind to it. This approach has been used to target DLEU7-AS1 in cancer cells and has been shown to be effective in preclinical studies.

Measurement of DLEU7-AS1 Levels

DLEU7-AS1 levels can be measured using various techniques, including Western blotting, immunofluorescence, and mass spectrometry. These techniques can be used to determine the level of DLEU7-AS1 in cancer cells and to monitor the effectiveness of an inhibitor or antibody in reducing DLEU7-AS1 levels.

Western blotting is a technique that can be used to measure the level of DLEU7-AS1 in cancer cells. This technique involves the use of antibodies that recognize DLEU7-AS1 and then measure the level of the protein in the cells. Western blotting can be used to determine the effectiveness of an inhibitor or antibody in reducing DLEU7-AS1 levels in cancer cells.

Immunofluorescence is another technique that can be used to measure the level of DLEU7-AS1 in cancer cells. This technique involves the use of antibodies that recognize DLEU7-AS1 and then visualize the protein in the cells. Immunofluorescence can be used to determine the effectiveness of an inhibitor or antibody in reducing DLEU7-AS1 levels in cancer cells.

Mass spectrometry is a technique that can be used to measure the level of DLEU7-AS1 in cancer cells. This technique involves the use of antibodies that recognize DLEU7-AS1 and then measure the level of the protein in the cells. Mass spectrometry can be used to determine the effectiveness of an inhibitor or antibody in reducing DLEU7-AS1 levels in cancer cells.

Conclusion

DLEU7-AS1 is a protein that has been associated with the development and progression of cancer. Recent studies have shown that DLEU7-AS1 can be a potential drug target and biomarker for cancer treatment. By using inhibitors that target the PI3K/Akt signaling pathway and antibodies that recognize and bind to DLEU7-AS1, researchers have been able to reduce the levels of DLEU7-AS1 in cancer cells. Further studies are needed to determine the effectiveness of these treatments

Protein Name: DLEU7 Antisense RNA 1

The "DLEU7-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DLEU7-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets